| Mrs Victoria Jayne Langford, AG-ACNP | |
|
1808 W Main St, Russellville, AR 72801-2724 | |
| (479) 968-2841 | |
| Not Available |
| Full Name | Mrs Victoria Jayne Langford |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Location | 1808 W Main St, Russellville, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1386340222 | NPI | - | NPPES |
| Entity Name | St Marys Physician Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124084991 PECOS PAC ID: 4981698032 Enrollment ID: O20040609000759 |
News Archive
One of the strongest known risk factors for spontaneous or unexpected preterm birth - any birth that occurs before the 37th week of pregnancy, most often without a known cause - is already having had one. For women in this group who would like to avoid this scenario in their second pregnancy, focusing on weight gain and dietary changes may not be the best strategy. A new study reported at the Society for Maternal-Fetal Medicine's annual meeting found no connection between weight gain and the risk of repeat preterm birth.
Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.
Sunscreens are one of the most essential means to protect oneself from the harmful UV rays of the sun and protect oneself from skin cancer. Skin cancer, say health officials, remains one of the most common cancers diagnosed in the United States.
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Victoria Jayne Langford, AG-ACNP 1225 E Elm St, Russellville, AR 72802-8684 Ph: (479) 857-6100 | Mrs Victoria Jayne Langford, AG-ACNP 1808 W Main St, Russellville, AR 72801-2724 Ph: (479) 968-2841 |
News Archive
One of the strongest known risk factors for spontaneous or unexpected preterm birth - any birth that occurs before the 37th week of pregnancy, most often without a known cause - is already having had one. For women in this group who would like to avoid this scenario in their second pregnancy, focusing on weight gain and dietary changes may not be the best strategy. A new study reported at the Society for Maternal-Fetal Medicine's annual meeting found no connection between weight gain and the risk of repeat preterm birth.
Researchers at Washington University School of Medicine in St. Louis have identified a chain reaction that triggers the regrowth of some damaged nerve cell branches, a discovery that one day may help improve treatments for nerve injuries that can cause loss of sensation or paralysis.
Sunscreens are one of the most essential means to protect oneself from the harmful UV rays of the sun and protect oneself from skin cancer. Skin cancer, say health officials, remains one of the most common cancers diagnosed in the United States.
ReVision Optics, a leading company in the research, development and manufacture of implantable medical devices designed to assist patients that need reading glasses, announced today that it has completed enrollment and initial follow up in Phase I of its US clinical trial and has filed for expansion. The clinical trial is for the study of the PresbyLens, recently renamed Vue+, for the improvement of near vision in patients with presbyopia, the age-related loss of near vision.
CSL Behring today announced a multi-year, $450 million two-site global capacity expansion – the latest in a series of recent production expansions to meet the growing need for its lifesaving and life-improving therapies that are used to treat patients with rare and serious medical disorders around the world.
› Verified 8 days ago